RAC 4.05% $1.54 race oncology ltd

Speculative M&A Transaction Analysis, page-848

  1. 1,252 Posts.
    lightbulb Created with Sketch. 12370
    They are fully funded for P2 CPACS which has a high chance of accelerated approval and peak global annual sales of $7b USD on 50% reduction to stated uptake.

    Stage IV asset typically get 5x peak sales.

    Honestly, man, do the maths.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.